MET 是一种原癌基因，可以驱动肺癌等多种恶性肿瘤的发生发展。MET 异常具有多种形式，包括 MET 扩增，MET 14 跳变，MET 蛋白过表达等。其中 MET 14 跳变 在 NSCLC 中尤为常见，发生率为 0.9%~4%[1]。MET 14 ...

MET 14 号外显子跳跃突变（MET 14 跳变）是非小细胞肺癌（NSCLC）的少见驱动基因靶点之一，通常与高侵袭性、抗肿瘤治疗的耐药性和不良预后相关[1,2]，给临床治疗带来了严峻挑战。而随着 MET 酪氨酸激酶抑制剂（TKI）的出现，不仅为 ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) compared ...

许多罕见靶点之所以被称为“难治”，核心原因之一并非药物无效，而是因为在疾病初期发生了漏检，从而错失了引入靶向治疗的最佳时机。因此，高质量、全面的基因检测不仅是战术选择，更是决定治疗成败的战略基石。

Trethera Corp. received a $2.7M NIH grant to study combining TRE-515 with KRAS inhibitors for lung cancer. Learn how this ...